Next Article in Journal
1-Benzyl-2-(thien-2-yl)-4,5-dihydro-1H-imidazole
Previous Article in Journal
3-(4-Bromophenyl)-4-{[3-hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl](m-tolyl)methyl}isoxazol-5(2H)-one
Open AccessShort Note

4-(3-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)thieno[3,2-d]pyrimidine

Department of Chemistry, Mokwon University, Doanbuk-Ro 88, Daejeon 35349, Korea
*
Author to whom correspondence should be addressed.
Molbank 2020, 2020(2), M1136; https://doi.org/10.3390/M1136
Received: 3 May 2020 / Revised: 15 May 2020 / Accepted: 17 May 2020 / Published: 17 May 2020

Abstract

A new hybrid compound, 4-(3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)thieno[3,2-d]pyrimidine 3, with promising biological activity was efficiently synthesized by the reaction of 3-phenyl-1-(thieno[3,2-d]pyrimidin-4-yl)-1H-pyrazol-5-amine with Vilsmeier–Haack reagent and subsequent treatment with ammonium carbonate. The structure of the synthesized compound was fully characterized by 1H-, 13C-NMR, IR spectroscopy, mass-spectrometry and elemental analysis.
Keywords: thieno[3,2-d]pyrimidine; pyrazolo[3,4-d]pyrimidine; Vilsmeier–Haack reagent thieno[3,2-d]pyrimidine; pyrazolo[3,4-d]pyrimidine; Vilsmeier–Haack reagent

1. Introduction

The thienopyrimidines and pyrazolopyrimidines have attracted considerable interest because of their various biological properties and therapeutic potentials [1,2,3,4]. Among them, thieno[3,2-d]pyrimidines were known to have pharmacological significance including anticancer [5], antitumor [6], antimicrobial [7], antiviral [8], and anti-inflammatory [9] activities. Pyrazolo[3,4-d]pyrimidines, which structurally resemble purines, have been reported to possess antiviral [10], anticancer [11], anti-inflammatory [12], antileishmanial [13] and antimicrobial [14] activities.
We have recently synthesized thienopyrimidine-pyrazolo[3,4-b]pyridine hybrids [15], and thienopyrimidines containing [1,2,4]triazolo[4,3-a]pyridinylpyrazole moiety as IL-6 inhibitor [16]. In the continuation of our research, we report herein the synthesis of a hybrid compound 3, thieno[3,2-d]pyrimidine bearing a pyrazolo[3,4-d]pyrimidine.

2. Results and Discussion

The synthesis of the new hybrid compound 3 is outlined in Scheme 1. The starting material 1, 3-phenyl-1-(thieno[3,2-d]pyrimidin-4-yl)-1H-pyrazol-5-amine, was prepared by our previously reported method [15]. Compound 1 was reacted with DMF and phosphorus oxychloride (Vilsmeier–Haack reagent) at 70 °C for 5 h to afford intermediate 2. Subsequent refluxing of the solution of 2 and ammonium carbonate in acetic acid resulted in the formation of compound 3, 4-(3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)thieno[3,2-d]pyrimidine, in 82% yield [17].
The structure of 3 was confirmed by 1H-, 13C-NMR, IR spectroscopy, mass-spectrometry and elemental analysis (see Supplementary Materials). The 1H-NMR spectrum of compound 3 showed three singlet signals at δ 9.95, 9.38 and 9.21 ppm due to two protons of newly formed pyrimidine ring and one proton of pyrimidine in thieno[3,2-d]pyrimidine ring. It presented also a pair of doublet signals at δ 8.61 and 7.74 (J = 5.8 Hz) attributed to thiophene protons of thieno[3,2-d]pyrimidine ring, and other multiplet signals for the phenyl ring. In the 13C-NMR spectrum, compound 3 exhibited characteristic peaks at δ 154.8 and 154.2 ppm for the newly formed pyrimidine carbons, including two pyrimidine peaks at δ 163.3 and 157.0 ppm in thieno[3,2-d]pyrimidine ring. The infrared (IR) spectrum of compound 3 revealed a characteristic absorption band at 1620 cm−1 for C=N bond stretching. The mass spectrum showed m/z = 331.21 corresponding the molecular formula, C17H10N6S. Elemental analysis also provided satisfactory results for compound 3.
The hybrid compound 3 was also obtained in 80% yield by the reaction of compound 1 with a modified Vilsmeier–Haack reagent, HCONH2 and POCl3, using the Wong’s method [18]. The spectral data of the resultant product were identical in all respects (mp, 1H-, 13C-NMR, and mass spectra) with the data of compound 3.
The inhibitor of IL-6 induced activation of STAT3 could be a useful candidate for the development of new anticancer and anti-inflammatory drugs [19]. The preliminary biological test of inhibitory activity on STAT3 dependent luciferase activity induced by IL-6 for compound 3 was performed, according to the reported method [16], and it exhibited an IC50 value of 2.55 µM. Genistein with IC50 value of 15.0 µM was used as positive control in this assay system [20].

3. Materials and Methods

3.1. General Information

Commercial reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and TCI (Tokyo, Japan). The solvents used were purified using standard techniques. Melting point was determined on Kofler apparatus and was uncorrected. The 1H-, and 13C-NMR spectrum were recorded in deuterated chloroform with TMS as the standard on a UNITY INOVA 400 NB FT-NMR. The UV spectrum was obtained using a Perkin-Elmer Lambda-25 UV-vis spectrophotometer. The IR spectrum was recorded on Shimazu FTIR Prestige-21 spectrometer. The mass spectrum was obtained with a Finnigan MAT INCOS50 instrument.

3.2. Synthesis of 4-(3-Phenyl-1H-Pyrazolo[3,4-d]Pyrimidin-1-yl)Thieno[3,2-d]Pyrimidine 3

(1)
Method using Vilsmeier–Haack reagent: A solution of 3-phenyl-1-(thieno[3,2-d]pyrimidin-4-yl)-1H-pyrazol-5-amine 1 (100 mg, 0.34 mmol) and POCl3 (0.10 mL, 1.1 mmol, 3.0 equiv) in DMF (3 mL) was heated at 70 °C with stirring for 5 h. The mixture was cooled to room temperature and evaporated to dryness. Acetic acid (5 mL) and ammonium carbonate (105 mg, 1.1 mmol) were added to the residue, the reaction mixture was heated under reflux for 5 h. When the reaction was completed, the mixture was added to saturated aqueous sodium bicarbonate (15 mL) and extracted with CH2Cl2 (2 × 15 mL). The organic extracts were dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (eluent: ethyl acetate/petroleum ether (bp 40–60 °C) = 1/10) to give the title compound 3 (92 mg, 82%) and recrystallized as light yellow needles, mp 263–264 °C (EtOH); TLC Rf = 0.25 (ethyl acetate/n-hexane = 20/80); 1H-NMR (400 MHz, CDCl3) δ 9.95 (s, 1H), 9.38 (s, 1H), 9.21 (s, 1H), 8.61 (d, J = 5.8 Hz, 1H), 8.36–8.34 (m, 2H), 7.74 (d, J = 5.8 Hz, 1H), 7.72–7.68 (m, 2H), 7.66–7.62 (m, 1H). 13C-NMR (100 MHz, CDCl3) 163.3, 157.0, 154.8, 154.2, 153.6, 152.2, 146.4, 141.4, 130.5, 130.0, 129.4 (2 × C), 127.5 (2 × C), 124.1, 118.5, 114.6. IR (KBr) 1620 (C = N), 755, 690 cm−1. UV (λmax in MeOH, log ε) 350 (4.15), 288 (3.90) nm. MS (APCI) m/z = 331.21 (MH+, 96%). Anal. calcd. for C17H10N6S, %: C, 61.80; H, 3.05; N, 25.44. Found, %: C, 61.95; H, 3.10; N, 25.51.
(2)
Direct method using a modified Vilsmeier–Haack reagent: A solution of 3-phenyl-1-(thieno[3,2-d]pyrimidin-4-yl)-1H-pyrazol-5-amine 1 (100 mg, 0.34 mmol) and POCl3 (0.10 mL, 1.1 mmol, 3.0 equiv) in formamide (3 mL) was heated at 60 °C with stirring for 5 h. After the completion, the reaction mixture was concentrated and worked-up in the same way as above. The residue was purified by column chromatography (eluent: ethyl acetate/petroleum ether (bp 40–60 °C) = 1/10) to give the title compound 3 (89 mg, 80%).

Supplementary Materials

The following are available online, Figure S1: 1H- and 13C-NMR spectra of compound 3, Figure S2: Mass spectrum of compound 3.

Author Contributions

E.S.N., S.M.K. and Y.-H.S. conceived and designed the experiments; E.S.N. and S.M.K. performed the experiments; Y.-H.S. analyzed data and wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

This work was supported by Mokwon University (Research Year Program).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ali, E.M.H.; Abdel-Maksoud, M.S.; Oh, C.-H. Thieno[2,3-d]pyrimidines as a promising scaffold in medicinal chemistry: Recent advances. Bioorg. Med. Chem. 2019, 27, 1159–1194. [Google Scholar] [CrossRef] [PubMed]
  2. Ghith, A.; Ismail, N.S.M.; Youssef, K.; Abouzid, K.A.M. Medicinal attributes of thienopyrimidine based scaffold targeting tyrosine kinases and their potential anticancer activities. Arch. Pharm. 2017, 350, 1700242. [Google Scholar] [CrossRef] [PubMed]
  3. Abdellatif, K.R.A.; Bakr, R.B. New advances in synthesis and clinical aspects of pyrazolo[3,4-d]pyrimidine scaffolds. Bioorg. Chem. 2018, 78, 341–357. [Google Scholar] [CrossRef] [PubMed]
  4. Chauhan, M.; Kumar, R. Medical attributes of pyrazolo[3,4-d]pyrimidines: A review. Bioorg. Med. Chem. Lett. 2013, 21, 5657–5668. [Google Scholar] [CrossRef] [PubMed]
  5. Romagnoli, R.; Prencipe, F.; Oliva, P.; Baraldi, S.; Baraldi, P.G.; Schiaffino Ortega, S.; Chayah, M.; Salvador, M.K.; Lopez-Cara, L.C.; Brancale, A.; et al. Design, synthesis, and biological evaluation of 6-substituted thieno[3,2-d]pyrimidine analogues as dual epidermal growth factor receptor kinase and microtubule inhibitors. J. Med. Chem. 2019, 2, 1274–1290. [Google Scholar] [CrossRef] [PubMed]
  6. Hu, H.; Dong, Y.; Li, M.; Wang, R.; Zhang, X.; Gong, P.; Zhao, Y. Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents. Bioorg. Chem. 2019, 90, 103086. [Google Scholar] [CrossRef] [PubMed]
  7. Hafez, H.N.; El-Gazzar, A.-R.B.A.; Zaki, M.E.A. Simple approach to thieno[3,2-d]pyrimidines as new scaffolds of antimicrobial activities. Acta Pharm. 2016, 66, 331–351. [Google Scholar] [CrossRef] [PubMed]
  8. Wang, Z.; Kang, D.; Chen, M.; Wu, G.; Feng, D.; Zhao, T.; Zhou, Z.; Huo, Z.; Jing, L.; Zuo, X.; et al. Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. Chem. Biol. Drug Des. 2018, 92, 2009–2021. [Google Scholar] [CrossRef] [PubMed]
  9. Barone, M.; Graziano, A.C.E.; Marrazzo, A.; Gemmellaro, P.; Santagati, A.; Cardile, V. Synthesis and biological evaluation of new benzo-thieno[3,2-d]pyrimidin-4-one sulphonamide thio-derivatives as potent selective cyclooxygenase-2 inhibitors. Mol. Divers. 2013, 17, 445–458. [Google Scholar] [CrossRef] [PubMed]
  10. Wang, Y.-Y.; Xu, F.-Z.; Zhu, Y.-Y.; Song, B.; Luo, D.; Yu, G.; Chen, S.; Xue, W.; Wu, J. Pyrazolo[3,4-d]pyrimidine derivatives containing a Schiff base moiety as potential antiviral agents. Bioorg. Med. Chem. Lett. 2018, 28, 2979–2984. [Google Scholar] [CrossRef] [PubMed]
  11. Cherukupalli, S.; Chandrasekaren, B.; Krystof, V.; Aleti, R.R.; Sayyad, N.; Merugu, S.R.; Kushwaha, N.D.; Karpoormath, R. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. Bioorg. Chem. 2018, 79, 46–59. [Google Scholar] [CrossRef] [PubMed]
  12. Tageldin, G.N.; Fahmy, S.M.; Ashour, H.M.; Khalil, M.A.; Nassra, R.A.; Labouta, I.M. Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidines as anti-inflammatory agents. Bioorg. Chem. 2018, 78, 358–371. [Google Scholar] [CrossRef] [PubMed]
  13. Feitosa, L.M.; da Silva, E.R.; Hoelz, L.V.B.; Souza, D.L.; Come, J.A.A.S.S.; Cardoso-Santos, C.; Batista, M.M.; Soeiro, M.N.C.; Boechat, N.; Pinheiro, L.C.S. New pyrazolopyrimidine derivatives as Leishmania amazonensis arginase inhibitors. Bioorg. Med. Chem. 2019, 27, 3061–3069. [Google Scholar] [CrossRef] [PubMed]
  14. Hassaneen, H.D.; Saleh, F.M.; Abdallah, T.A.; Mohamed, M.F.; Mohamed, Y.S.; Awad, E.M.; Abdelhamid, I.A. Synthesis, cytotoxicity, antimicrobial and docking simulation of novel pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e]triazolo[3,4-c]pyrimidine derivatives. Mini Rev. Med. Chem. 2019, 19, 657–670. [Google Scholar] [CrossRef] [PubMed]
  15. Park, J.W.; Song, Y.-H. Synthesis of thienopyrimidine-pyrazolo[3,4-b]pyridine hybrids. Heterocycl. Commun. 2017, 23, 281–285. [Google Scholar] [CrossRef]
  16. Jang, H.-J.; Kim, S.M.; Rho, M.-C.; Lee, S.W.; Song, Y.-H. Synthesis of thienopyrimidine derivatives as inhibitors of STAT3 activation induced by IL-6. J. Microbiol. Biotechnol. 2019, 29, 856–862. [Google Scholar] [CrossRef] [PubMed]
  17. Simay, A.; Takacs, K.; Horvath, K.; Dvortsak, P. Vilsmeier-Haack reaction of 5-amino- and 5-acylaminopyrazoles. Acta Chim. Acad. Sci. Hung. 1980, 105, 127–140. [Google Scholar]
  18. Chang, C.-H.; Tsai, H.J.; Huang, Y.-Y.; Lin, H.-Y.; Wang, L.Y.; Wu, T.S.; Wong, F.F. Selective synthesis of pyrazolo[3,4-d]pyrimidine, N-(1H-pyrazol-5-yl)formamide, or N-(1H-pyrazol-5-yl)formamidine derivatives from N-1-substituted-5-aminopyrazoles with new Vilsmeier-type reagents. Tetrahedron 2013, 69, 1378–1386. [Google Scholar] [CrossRef]
  19. Zhang, M.; Zhu, W.; Li, Y. Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening. Eur. J. Med. Chem. 2013, 62, 301–310. [Google Scholar] [CrossRef] [PubMed]
  20. Li, H.-C.; Zhang, G.-Y. Inhibitory effect of genistein on activation of STAT3 induced by brain ischemia/reperfusion in rat hippocampus. Acta Pharmacol. Sin. 2003, 24, 1131–1136. [Google Scholar] [PubMed]
Scheme 1. Synthesis strategy for the hybrid compound 3.
Scheme 1. Synthesis strategy for the hybrid compound 3.
Molbank 2020 m1136 sch001
Back to TopTop